Marcos Antonio Tambascia

Marcos Antonio Tambascia

Auto-generated profile, based on publicly available information

Marcos Antonio Tambascia

Endocrinology Division, Faculty of Medical Sciences, University of Campinas, Rua Tessália Vieira de Camargo 126, 13084-971 Campinas, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2014 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
AQAlessandra Quintino-Moro
Alessandra Quintino-Moro
DZDenise E. Zantut-Wittmann
Denise E. Zantut-Wittmann
MTMarcos Tambascia
Marcos Tambascia
HMHelymar da Costa Machado
Helymar da Costa Machado
AFArlete Fernandes
Arlete Fernandes
Objectives. To evaluate the prevalence of infertility in women with Graves’ disease (GD) or Hashimoto’s thyroiditis (HT) and associated factors.Material and Methods. This cross-sectional study was conducted at the Endocrinology Clinic for Thyroid Autoimmune Diseases, with 193 women aged 18–50 years with GD and 66 women aged 18–60 years with HT. The women were interviewed to obtain data on their gynecological and obstetric history and family history of autoimmune diseases. Their medical records were reviewed to determine the characteristics of the disease and to confirm association with other autoimmune diseases. Infertility was defined as 12 months of unprotected sexual intercourse without conception.Results. The prevalence of infertility was 52.3% in GD and 47.0% in HT. Mean age at diagnosis was 36.5 years and 39.2 years, in GD and HT, respectively. The mean number of pregnancies was lower in women who were 35 years old or younger at diagnosis and was always lower following diagnosis of the disease, irrespective of age. The only variable associated with infertility was a shorter time of the disease in HT.Conclusions. The prevalence of infertility was high in women with GD and HT and affected the number of pregnancies in young women.

26 June 2015 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
MTMarcos Antonio Tambascia
Marcos Antonio Tambascia
FEFreddy Goldberg Eliaschewitz
Freddy Goldberg Eliaschewitz
The development of extended-action insulin analogues was motivated by the unfavorable pharmacokinetic (PK) profile of the conventional long-acting insulin formulations, generally associated with marked inter and intra patient variability and site- and dose-dependent effect variation. The new ultra-long insulin analogue degludec (IDeg) has the same amino acid sequence as human insulin except for the removal of threonine in the position 30 of the B chain (Des-B30, “De”) and the attachment, via a glutamic acid linker (“glu”), of a 16-carbon fatty diacid (hexadecanoic diacid, “dec”) to lysine in the position 29 of the B chain. These modifications allow that, after changing from the pharmaceutical formulation to the subcutaneous environment, IDeg precipitates in the subcutaneous tissue, forming a depot that undergoes a highly predictable gradual dissociation. Thus, once-daily dosing of IDeg results in a low peak: trough ratio, with consequent low intra-individual variability and plasmatic concentrations less critically dependent upon the time of injections. The clinical development program of IDeg (BEGIN) was comprised of 9 therapeutic confirmatory trials of longer duration (26–52 weeks) and showed that the efficacy of IDeg is comparable to insulin glargine in type 1 (T1D) and type 2 (T2D) diabetes patients across different age, body mass index and ethnic groups. This new ultra-long insulin analogue presents as advantages flexibility in dose timing and lower risk of hypoglycemia.

27 August 2003 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
MTM. A. Tambascia
M. A. Tambascia
BGB. Geloneze
B. Geloneze
ERE. M. Repetto
E. M. Repetto
SGS. R. Geloneze
S. R. Geloneze
MPM Picolo
M Picolo
DMDaniela Oliveira Magro
Daniela Oliveira Magro

1 January 2019 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
RCRiobaldo Cintra
Riobaldo Cintra
FMFilipe A Moura
Filipe A Moura
LCLuiz Sergio F Carvalho
Luiz Sergio F Carvalho
JBJoaquim Barreto
Joaquim Barreto
MTMarcos Tambascia
Marcos Tambascia
ASAndrei C Sposito
Andrei C Sposito
SUMMARY The prevalence of type 2 diabetes mellitus (T2DM) in the elderly grew sharply over the last decade. Reduced insulin sensitivity and secretory capacity, weight gain, sarcopenia, and elevated adiposity are all common metabolic and body changes in the aging population that favor an increased risk of hypoglycemia, frailty syndrome, falls, and cognitive dysfunction. First line antidiabetic therapy is frequently not safe in older individuals because of its high risk of hypoglycemia and prevalent co-morbid diseases, such as chronic kidney disease, osteoporosis, cardiovascular disease, and obesity. Sodium-glucose cotransporter 2 inhibitor (SGLT2i) is a new class of antidiabetic therapy that inhibits glucose and sodium reabsorption on renal proximal convoluted tubule. Its effect is well demonstrated in various clinical scenarios in the younger population. This review and metanalysis describe particularities of the SGLT2i on the elderly, with mechanistic insights of the potential benefit and remaining challenges about the use of these drugs in this important age group. Further, we will present a meta-analysis of the main effects of SGLT2i reported in post-hoc studies in which the median age of the subgroups analyzed was over 60 years. Despite the absence of specific clinical trials for this population, our findings suggest that SGLT2i therapy on older individuals is effective to lower glucose and maintain its effect on systolic blood pressure and body weight.

25 May 2013 in ISRN Endocrinology
Verified
Journal Article
Open access
PDF file
PLPriscila Carneiro Moreira Lima
Priscila Carneiro Moreira Lima
ANArnaldo Moura Neto
Arnaldo Moura Neto
MTMarcos Antonio Tambascia
Marcos Antonio Tambascia
DZDenise Engelbrecht Zantut-Wittmann
Denise Engelbrecht Zantut-Wittmann
Objectives. Assess the prevalence of thyroid nodules and predictors of malignant origin in patients with autoimmune thyroid diseases. Patients and Methods. Retrospective study including 275 patients, 198 with Graves' disease and 77 with Hashimoto’s thyroiditis. Clinical and demographical data, ultrasonographical nodule characteristics, total thyroid volume and histological characteristics were recorded. Results. Graves’ disease: the prevalence of thyroid nodules and thyroid carcinoma were 27.78% and 5.05%, respectively. Older age (OR = 1.054; 95% CI = 1.029–1.080) and larger thyroid volumes (OR = 1.013; 95% CI = 1.003–1.022) increased the chance of nodules. Younger age (OR = 1.073; 95% CI = 1.020–1.128) and larger thyroid volume (OR = 1.018; 95% CI = 1.005–1.030) predicted thyroid carcinoma. Hashimoto’s thyroiditis: the prevalence of thyroid nodules and carcinomas were 50.7% and 7.8%, respectively. Nodules were predicted by thyroid volume (OR = 1.030; 95% CI = 1.001–1.062). We found higher number of nodules in patients with thyroid carcinoma than in those with benign nodules (3 versus 2; ). Patients with Hashimoto’s thyroiditis presented nodules more frequently than patients with Graves’ disease (50.65% versus 27.28%; ), while the prevalence of carcinoma was similar (). Conclusions. Larger goiter was associated with carcinoma in Graves’ disease and Hashimoto’s thyroiditis. Younger patients presented higher risk of papillary thyroid carcinoma in Graves’ disease. The prevalence of carcinoma was similar in both conditions.

1 April 2004 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
DMDilina N. Marreiro
Dilina N. Marreiro
BGBruno Geloneze
Bruno Geloneze
MTMarcos A. Tambascia
Marcos A. Tambascia
ALAntonio C. Lerário
Antonio C. Lerário
AHAlfredo Halpern
Alfredo Halpern
SCSilvia M.F. Cozzolino
Silvia M.F. Cozzolino
Essa revisão relata os aspectos etiológicos da resistência à insulina, bem como a participação do zinco nesse processo. O zinco participa de vias metabólicas que envolvem a síntese de proteínas, metabolismo de carboidratos, de lipídeos e de ácidos nucléicos. Esse mineral tem sido relacionado com a interação entre hormônios e seus receptores, e com melhoras no estímulo pós-receptor. Estudos in vitro apontam que a insulina pode se ligar com o zinco, melhorando a solubilidade deste hormônio nas células beta do pâncreas, e, ainda, pode aumentar a capacidade de ligação da insulina ao seu receptor. Na obesidade e resistência à insulina, têm sido detectadas alterações na concentração e na distribuição de zinco nos tecidos, bem como melhora da sensibilidade à insulina após a suplementação com esse mineral. Portanto, o papel metabólico do zinco na síndrome de resistência insulínica deve ser mais pesquisado, tendo em vista que esse mineral pode contribuir no controle das alterações metabólicas comumente presentes em pacientes obesos.